This stock comparison examines two companies whose fortunes are linked to the same scientific platform—messenger RNA (mRNA)—yet which play very different roles in that ecosystem. MRNA (Moderna) is a therapeutic and vaccine developer whose shares have experienced dramatic relative performance in recent months. MRVI (Maravai LifeSciences) supplies the raw materials and testing services that mRNA developers rely on. Growth-oriented investors tracking high-momentum biotech, as well as those evaluating a turnaround with asymmetric risk, may find this comparison useful for understanding how market positioning, catalysts, and risk profiles diverge between the two names.
Moderna develops medicines and vaccines based on messenger RNA (mRNA), the genetic instructions that cells use to make proteins. Following years of post-pandemic revenue contraction, recent market activity has reflected a sharp shift in sentiment. In 2026, the stock has risen substantially, with much of the move tied to positive late-stage results for intismeran autogene, a personalized mRNA-based cancer therapy developed with Merck, alongside the first U.S. Food and Drug Administration (FDA) approval of an mRNA-based seasonal flu vaccine. Broader catalysts—including early-stage hantavirus research, a next-generation COVID shot gaining market share, and addition to the Nasdaq-100 index—have reinforced the rally.
Despite the momentum, the fundamentals remain stretched by conventional measures. Moderna continues to report net losses, with trailing-twelve-month sales lower than a year earlier and an operating loss exceeding revenue. Recent weeks have also brought elevated volatility, including sharp single-day pullbacks as investors reassessed trial expectations and valuation. This combination of powerful catalysts and thin near-term profitability defines the current risk profile of MRNA.
Maravai LifeSciences operates as a supplier to the biopharmaceutical industry rather than a drug developer. Its two main segments are TriLink BioTechnologies, which produces mRNA-related reagents including the CleanCap capping technology, and Cygnus Technologies, which provides bioprocess impurity testing such as host cell protein (HCP) assays. This positions the company as a leveraged play on mRNA research and manufacturing activity across the industry.
Recent quarters have shown a gradual improvement in operating performance. Revenue has grown year over year, gross margins have expanded, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) has swung positive, prompting management to raise its full-year profitability outlook. The company has also refinanced its debt to extend maturities. However, the turnaround remains incomplete: MRVI still posts net losses on a GAAP (Generally Accepted Accounting Principles) basis, revenue can be lumpy due to large, infrequent orders, and a recent quarterly report included a substantial goodwill impairment and a lowered revenue outlook, illustrating the uneven nature of the recovery.
Tickeron's Trending AI Robots page curates a selection of the platform's AI trading bots, drawn from a broader library of hundreds of automated strategies that trade thousands of different tickers. Because market conditions change, only a subset of these bots—those judged most suitable for the current environment—earns a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades, offering a range of approaches for different objectives. For traders seeking a systematic, data-driven way to evaluate setups like the MRNA and MRVI comparison, exploring Trending AI Robots can provide additional quantitative context.
The most fundamental contrast between these two stocks is their business model. Moderna bears development and regulatory risk in pursuit of blockbuster-scale products, while Maravai earns revenue by selling tools and services into the same industry, trading scale for a broader customer base. On growth drivers, Moderna's story centers on a few high-impact catalysts—cancer vaccines, respiratory vaccines, and geographic expansion—whereas Maravai's outlook depends on a wider recovery in biopharma research spending and steady conversion of discovery-stage customers into clinical-grade orders.
Recent momentum differs sharply. MRNA has posted exceptional returns but with elevated volatility and a valuation tied to products not yet selling in volume. MRVI has advanced more modestly, supported by margin improvement and balance-sheet repair, but remains constrained by persistent net losses, order lumpiness, and meaningful short interest. In terms of sector exposure, both carry biotech sensitivity, yet Moderna is a concentrated, high-beta (a measure of volatility relative to the broader market) growth name, while Maravai functions more as a diversified, cyclical supplier to the industry's research pipeline.
Weighing observable factors—trend consistency, catalyst strength, and relative positioning—Tickeron's AI currently leans toward MRNA over MRVI. Moderna's sustained uptrend, multiple clinical and regulatory catalysts, and expanding market recognition provide a more clearly defined momentum profile, even as its valuation and volatility warrant caution. Maravai's improving fundamentals are credible but remain uneven and partly dependent on factors outside its control, such as customer order timing. Accordingly, the AI would likely favor MRNA on a relative basis, while acknowledging that both names carry meaningful risk in the current environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for MRNA moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
MRNA moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 108 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.010) is normal, around the industry mean (3.596). P/E Ratio (-31.853) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRVI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 32 similar instances where the stock broke above the upper band. In 30 of the 32 cases the stock fell afterwards. This puts the odds of success at 90%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRVI as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for MRVI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
MRVI moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for MRVI crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +14.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.475) is normal, around the industry mean (3.596). P/E Ratio (-14.189) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRNA | MRVI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 97 | |
PRICE GROWTH RATING 1..100 | 34 | 37 | |
P/E GROWTH RATING 1..100 | 99 | 58 | |
SEASONALITY SCORE 1..100 | 90 | 7 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRNA's Valuation (10) in the Biotechnology industry is in the same range as MRVI (15) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.
MRNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRVI (100) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.
MRNA's SMR Rating (97) in the Biotechnology industry is in the same range as MRVI (97) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.
MRNA's Price Growth Rating (34) in the Biotechnology industry is in the same range as MRVI (37) in the null industry. This means that MRNA’s stock grew similarly to MRVI’s over the last 12 months.
MRVI's P/E Growth Rating (58) in the null industry is somewhat better than the same rating for MRNA (99) in the Biotechnology industry. This means that MRVI’s stock grew somewhat faster than MRNA’s over the last 12 months.
| MRNA | MRVI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Advances ODDS (%) | 13 days ago 78% | 13 days ago 79% |
| Declines ODDS (%) | 4 days ago 87% | 1 day ago 83% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 83% | N/A |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRNA’s FA Score shows that 1 FA rating(s) are green while MRVI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRNA’s TA Score shows that 3 TA indicator(s) are bullish while MRVI’s TA Score has 3 bullish TA indicator(s).
MRNA (@Biotechnology) experienced а -12.70% price change this week, while MRVI (@Biotechnology) price change was -7.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
MRNA is expected to report earnings on Feb 25, 2027.
MRVI is expected to report earnings on Feb 24, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, MRVI has been loosely correlated with TWST. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRVI jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To MRVI | 1D Price Change % | ||
|---|---|---|---|---|
| MRVI | 100% | -2.92% | ||
| TWST - MRVI | 50% Loosely correlated | -7.44% | ||
| MRNA - MRVI | 47% Loosely correlated | -2.17% | ||
| RXRX - MRVI | 46% Loosely correlated | -9.93% | ||
| ARCT - MRVI | 43% Loosely correlated | -1.97% | ||
| BNTX - MRVI | 43% Loosely correlated | -0.52% | ||
More | ||||